Aaps Advances in the Pharmaceutical Sciences

.- I Introduction .- 1 Antibody-Drug Conjugates: A Historical Review (Wei-Chiang Shen) .- II The ADC Construct .- 2 Payloads of Antibody-Drug Conjugates (Chalet Tan) .- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy (Michael Ritchie, Laird Bloom, Gregory Carven, and Puja Sapra) .- 4 Linker Design for Antibody-Drug Conjugates (E. Erica Hong and Ravi Chari) .- III Development Issues .- 5 Formulation Development for Antibody-Drug Conjugates (Junyan A. Ji, Jun Liu, Y. John Wang) .- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates (Chen Xie and Zhijun Wang) .- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates (Siddharth Sukumaran and Kedan Lin) .- 8 Regulatory Considerations (Karen J. Cha) .- IV Landscape, IP and Pharmacoeconomics .- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy (Jeffrey Wang and Jonathan H. Watanabe) .- V Case Studies .- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal (Jennica L. Zaro) .- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate (Bruce W. Hart Jr.) .- 12 Ado-Trastuzumab Emtansine (Yun Luo, Jerome J. Lacroix and Sunil Prabhu) .- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer (Nancy Chan and Linda T. Vahdat) .- VI From Today to Tomorrow .- 14 Summary and Future Directions (Jennica L. Zaro, Jeffery Wang and Wei-Chiang Shen).